| scholarly article | Q13442814 |
| P50 | author | Henrik Grönberg | Q28466382 |
| Seong-tae Kim | Q43089035 | ||
| Johan Lindberg | Q55755987 | ||
| Jianfeng Xu | Q67190177 | ||
| George S. Bova | Q67482691 | ||
| William B Isaacs | Q89161930 | ||
| Xie Chunmei | Q92543517 | ||
| Wennuan Liu | Q101050166 | ||
| S Lilly Zheng | Q114387461 | ||
| Jielin Sun | Q114406220 | ||
| A Karim Kader | Q114718043 | ||
| P2093 | author name string | Zheng Zhang | |
| Zhong Wang | |||
| Lars Egevad | |||
| Patrick P Koty | |||
| Scott D Cramer | |||
| Jishan Sun | |||
| Christopher Y Thomas | |||
| P2860 | cites work | Gene expression profiling predicts clinical outcome of prostate cancer | Q24594253 |
| Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer | Q24616117 | ||
| The genomic complexity of primary human prostate cancer | Q24617949 | ||
| FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. | Q27851411 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach | Q29614698 | ||
| Integrative genomic profiling of human prostate cancer | Q29619905 | ||
| Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma | Q30014823 | ||
| Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer | Q30866782 | ||
| Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy | Q33361134 | ||
| Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer | Q33730189 | ||
| Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study | Q34179268 | ||
| Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer | Q35115736 | ||
| Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. | Q36638686 | ||
| SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression | Q37120753 | ||
| Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer | Q37136805 | ||
| Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate | Q39506775 | ||
| Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins | Q39959273 | ||
| Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis | Q46695435 | ||
| Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer | Q47895920 | ||
| Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition | Q56906348 | ||
| Radical prostatectomy versus watchful waiting in early prostate cancer | Q57137210 | ||
| Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy | Q57790286 | ||
| Survival Among Men With Clinically Localized Prostate Cancer Treated With Radical Prostatectomy or Radiation Therapy in the Prostate Specific Antigen Era | Q62746689 | ||
| Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer | Q74449219 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2405-2412 | |
| P577 | publication date | 2013-04-22 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Genetic markers associated with early cancer-specific mortality following prostatectomy | |
| P478 | volume | 119 |
| Q37029385 | Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools |
| Q37578965 | An expression signature at diagnosis to estimate prostate cancer patients' overall survival |
| Q38833458 | Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. |
| Q51033341 | Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. |
| Q42370830 | Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data |
| Q38966736 | Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. |
| Q37474443 | Biomarkers for prostate cancer: present challenges and future opportunities |
| Q43119437 | C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance. |
| Q42140241 | Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation |
| Q37221588 | Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer |
| Q34002312 | Copy number alteration burden predicts prostate cancer relapse |
| Q89767735 | Copy number alterations are associated with metastatic-lethal progression in prostate cancer |
| Q59335329 | Correlation between genomic index lesions and mpMRI and Ga-PSMA-PET/CT imaging features in primary prostate cancer |
| Q91669790 | Current progress and questions in germline genetics of prostate cancer |
| Q38774228 | DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer |
| Q41439657 | Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy |
| Q38794112 | Genomic predictors for treatment of late stage prostate cancer |
| Q38220416 | High-risk prostate cancer: a disease of genomic instability |
| Q36106271 | Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study |
| Q47399099 | MYC overexpression at the protein and mRNA level and cancer outcomes among men treated with radical prostatectomy for prostate cancer |
| Q38668635 | Molecular biomarkers to guide precision medicine in localized prostate cancer |
| Q55156621 | Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. |
| Q41912121 | PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. |
| Q42371556 | PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort |
| Q37113160 | Personalized prostate cancer care: from screening to treatment |
| Q91896538 | Polyalthia longifolia Extract Triggers ER Stress in Prostate Cancer Cells Concomitant with Induction of Apoptosis: Insights from In Vitro and In Vivo Studies |
| Q38184382 | Prognostic prostate tissue biomarkers of potential clinical use. |
| Q42748239 | Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer |
| Q39044979 | Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma |
| Q36931932 | Should Gleason 6 be labeled as cancer? |
| Q33921151 | Systematic identification and characterization of RNA editing in prostate tumors |
| Q35693808 | TPD52 expression increases neutral lipid storage within cultured cells. |
| Q92410942 | The Role of RB in Prostate Cancer Progression |
| Q38203985 | The epidemiology and clinical implications of genetic variation in prostate cancer |
| Q47144748 | Tissue-based biomarkers in prostate cancer |
| Q38209599 | Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? |
| Q38540198 | Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer |
| Q37688990 | c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer |
Search more.